IGF1 and cancer: Additionally, hypoxia-induced senescent CAFs (hsCAFs) secrete IGF-I to suppress AMP-activated protein kinase (AMPK) activity, thereby sustaining cancer stemness and contributing to chemoresistance and adverse clinical outcomes [36].